Data gathered: September 16
AI Stock Analysis - Black Diamond Therapeutics (BDTX)
Analysis generated September 13, 2025. Powered by Chat GPT.
Black Diamond Therapeutics is an innovative biotechnology company focused on discovering and developing precision medicines for genetically defined cancers with limited treatment options. The company employs its proprietary Mutation Allostery Pharmacology (MAP) platform to identify and target new drug candidates. Specializing in precision oncology, Black Diamond Therapeutics aims to address significant unmet medical needs and provide breakthrough treatments for cancer patients.
Stock Alerts - Black Diamond Therapeutics (BDTX)
 |
Black Diamond Therapeutics | September 9 Price is up by 6.4% in the last 24h. |
|
Black Diamond Therapeutics | August 22 Price is up by 7.6% in the last 24h. |
|
Black Diamond Therapeutics | August 13 Price is up by 7.9% in the last 24h. |
|
Black Diamond Therapeutics | August 12 Price is up by 9.1% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Black Diamond Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Employee Rating | 76 | Sign up | Sign up | Sign up |
| Google Trends | 5 | Sign up | Sign up | Sign up |
| Patents | 5 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 18 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,653 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 26 | Sign up | Sign up | Sign up |
| Linkedin Employees | 35 | Sign up | Sign up | Sign up |
About Black Diamond Therapeutics
Black Diamond Therapeutics, Inc., a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers.
| Price | $3.19 |
| Target Price | Sign up |
| Volume | 905,790 |
| Market Cap | $185M |
| Year Range | $1.25 - $3.37 |
| Dividend Yield | 0% |
| PE Ratio | 13.54 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Black Diamond Therapeutics initiated with bullish view at Guggenheim, here's whySeptember 4 - Thefly.com |
|
Black Diamond Therapeutics initiated with bullish view at GuggenheimSeptember 3 - Thefly.com |
 |
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives $12.40 Average PT from BrokeragesSeptember 1 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 0 | 0 | 0 | -11M | -13M | -0.190 |
| Q1 '25 | 70M | 0 | 70M | 57M | 55M | 0.980 |
| Q4 '24 | 0 | 0 | 0 | -16M | -18M | -0.280 |
| Q3 '24 | 0 | 86,000 | -86,000 | -16M | -18M | -0.275 |
| Q2 '24 | 0 | 86,000 | -86,000 | -20M | -22M | -0.360 |
Insider Transactions View All
| BB BIOTECH AG filed to sell 7,217,839 shares at $1.9. March 20 '25 |
| BB BIOTECH AG filed to sell 3,817,839 shares at $2.1. March 20 '25 |
| BB BIOTECH AG filed to sell 2,733,547 shares at $2.1. March 20 '25 |
| BB BIOTECH AG filed to sell 3,233,547 shares at $2. March 20 '25 |
| BB BIOTECH AG filed to sell 6,217,839 shares at $2.3. March 20 '25 |
Similar companies
Read more about Black Diamond Therapeutics (BDTX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Black Diamond Therapeutics?
The Market Cap of Black Diamond Therapeutics is $185M.
What is Black Diamond Therapeutics' PE Ratio?
As of today, Black Diamond Therapeutics' PE (Price to Earnings) ratio is 13.54.
What is the current stock price of Black Diamond Therapeutics?
Currently, the price of one share of Black Diamond Therapeutics stock is $3.19.
How can I analyze the BDTX stock price chart for investment decisions?
The BDTX stock price chart above provides a comprehensive visual representation of Black Diamond Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Black Diamond Therapeutics shares. Our platform offers an up-to-date BDTX stock price chart, along with technical data analysis and alternative data insights.
Does BDTX offer dividends to its shareholders?
As of our latest update, Black Diamond Therapeutics (BDTX) does not offer dividends to its shareholders. Investors interested in Black Diamond Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Black Diamond Therapeutics?
Some of the similar stocks of Black Diamond Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.